Our findings provide direct human genetic evidence to support prior studies investigating the beneficial effect of the FGFR1 signaling pathway as a therapeutic target of diabetes and obesity in humans. Here, FGFR1 is linked to obesity due to melanocortin 4 receptor deficiency.